Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR428926 in advanced solid tumors
NCT02575781Phase 1Completed
- Sponsor
- Sanofi
- Start
- Oct 2015
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of SAR428926 in solid tumor and triple-negative breast cancer (TNBC) (3 cohorts), sponsored by Sanofi. Primary endpoints: Dose Limiting Toxicities at 4 weeks, Corneal Adverse Events at 8 weeks and 1 more. Started Oct 2015; status: completed.
02
Drugs
SAR428926
03
Conditions
solid tumortriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02575781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02575781.